Election campaign
Novo Nordisk agrees to lower certain drug prices in the US
The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid
Lilly announces agreement with US government to lower patient costs
The agreement will make insulin and obesity treatments more affordable through federal programmes and direct-to-patient channels
NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine
More than 11,000 people are diagnosed with head and neck cancers every year in England
Navigating NHS Market Access: Policy Change and Opportunity in England
With the changes at NHS England and the publishing of the 10-Year Plan, there is a lot of talk of change in the NHS in England. But what do these...
Digital Transformation in the NHS’s 10-Year Plan: Techno-Optimism and the Limits of Efficiency
Here, Evelyne Priestman (Senior Consultant – HEOR) and Mary Baker (Senior Medical Writer) at Petauri Evidence explore the National Health Service (NHS) in England’s newly unveiled 10-year plan through the...
Live Q&A: Beyond NHS England – Navigating changes at NHSE and DHSC
What impact can we expect from the abolition of NHS England (NHSE) and changes at the Department of Health and Social Care (DHSC)? What do these changes mean for your...
Live Q&A: Beyond NHS England – Restructuring and its implications for Pharma and Medtech
What does the abolition of NHS England mean for your market access and NHS Engagement strategy? How will the changes at national and integrated care board (ICB) level impact launch...
The abolition of NHS England: Navigating NHS restructuring and its impact on the pharmaceutical industry
Last week Prime Minister Sir Keir Starmer announced the abolition of NHS England to "cut bureaucracy" and bring management of the health service "back into democratic control". This significant change...
Prime minister unveils UK government’s plans to abolish NHS England
The move aims to cut waiting times and free up money for front-line services
NHS England appoints Sir James Mackey as CEO
Mackey is currently serving as chief executive of Newcastle Hospitals NHS Foundation Trust
NHS England begins newborn screening programme to identify rare genetic conditions
The Generation Study is aiming to screen 100,000 newborns for more than 200 diseases
What is willingness to pay? – Comparing price testing methodologies
Heather Wellam (Senior Consultant – Market Access, Mtech Access) explores the concept of willingness to pay (WTP) and what it means for pharmaceutical and medtech pricing strategy. Read on to...